TD Asset Management Inc Purchases 7,386 Shares of Bio-Rad Laboratories, Inc. $BIO

TD Asset Management Inc increased its position in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 461.0% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 8,988 shares of the medical research company’s stock after acquiring an additional 7,386 shares during the period. TD Asset Management Inc’s holdings in Bio-Rad Laboratories were worth $2,520,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. Quent Capital LLC bought a new position in Bio-Rad Laboratories in the third quarter valued at about $25,000. Farther Finance Advisors LLC increased its position in shares of Bio-Rad Laboratories by 52.9% during the 3rd quarter. Farther Finance Advisors LLC now owns 104 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 36 shares during the last quarter. Geneos Wealth Management Inc. lifted its stake in shares of Bio-Rad Laboratories by 115.2% in the 2nd quarter. Geneos Wealth Management Inc. now owns 142 shares of the medical research company’s stock worth $34,000 after purchasing an additional 76 shares during the period. CWM LLC boosted its holdings in shares of Bio-Rad Laboratories by 82.0% in the third quarter. CWM LLC now owns 202 shares of the medical research company’s stock worth $57,000 after buying an additional 91 shares during the last quarter. Finally, UMB Bank n.a. boosted its holdings in shares of Bio-Rad Laboratories by 24.0% in the third quarter. UMB Bank n.a. now owns 207 shares of the medical research company’s stock worth $58,000 after buying an additional 40 shares during the last quarter. Hedge funds and other institutional investors own 65.24% of the company’s stock.

Bio-Rad Laboratories Trading Up 1.7%

Shares of BIO stock opened at $284.83 on Thursday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.19 and a current ratio of 5.62. The stock has a fifty day simple moving average of $296.91 and a two-hundred day simple moving average of $301.34. The firm has a market capitalization of $7.69 billion, a PE ratio of 10.21 and a beta of 1.18. Bio-Rad Laboratories, Inc. has a 52-week low of $211.43 and a 52-week high of $343.12.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings data on Thursday, February 12th. The medical research company reported $2.51 EPS for the quarter, missing the consensus estimate of $2.57 by ($0.06). Bio-Rad Laboratories had a net margin of 29.42% and a return on equity of 3.86%. The business had revenue of $693.20 million during the quarter, compared to analysts’ expectations of $694.64 million. During the same quarter in the previous year, the firm earned $2.90 earnings per share. Bio-Rad Laboratories’s revenue was up 3.9% on a year-over-year basis. On average, analysts predict that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

BIO has been the topic of several recent research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Bio-Rad Laboratories in a research report on Monday, December 29th. Wall Street Zen lowered Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $358.50.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.